Table 2.
LSD | Signs and symptoms | Course of the disease |
---|---|---|
FD |
Main symptoms at onset: fatigue, pain, fever crisis, digestive discomfort, heat stroke, pain in the extremities, foam in the urine, etc Early presence of symptoms in paediatric age |
Shortened life expectancy and a significant loss of quality of life FD progression in target organs such as heart or kidneys, such as kidney failure, cardiomyopathy, and cerebrovascular ischemic events (stroke) with irreversible consequences for the patient |
GD |
The most common sign is a swollen spleen, which can be followed by bone disease and brain involvement and other problems such as tiredness, bleeding, bruising, and lung disease Pain due to bone or neuronal involvement is the most common reason for consultation Thrombocytopenia and anemia |
Degenerative disease that can progress to increased visceromegaly (hepatomegaly and splenomegaly), recurrent bone pain, and lung involvement |
PD |
Symptoms little visible at onset with low impact on quality of life initially The first symptoms are: muscle weakness and difficulty walking, breathing problems and infections of the respiratory system and failure to gain weight and growth at the expected rate. HyperCKemias |
Muscle weakness (which can make it very difficult to walk), and breathing problems, that will finally lead to the use of walking aids and mechanical ventilation |
MPSI | In the first years of life, patients present visible musculoskeletal alterations of varying degree, as well as corneal opacity |
Very disabling degenerative disease that affects children in its most serious forms High impact on quality of life due to physical limitations and cardiovascular and respiratory complications |
These four LSD have a wide range of clinical presentation and different phenotypes exists
FD: Fabry disease; GD: Gaucher disease; PD: Pompe disease; MPSI: mucopolysaccharidosis type 1